Integra LifeSciences has entered into a definitive agreement to acquire Derma Sciences, a medtech specializing in tissue regeneration for advanced wound and burn care.
Hill-Rom has signed a definitive agreement to acquire Mortara Instrument Inc. for an estimated $330 million. Integration of Mortara’s portfolio is expected to expand and enhance Hill-Rom’s offerings in the diagnostic cardiology and vital sign monitoring markets, as well as accelerate growth for Mortara technology on a global scale.
Support for a swift repeal of the Affordable Care Act (ACA) is wavering in the U.S. Senate, as many express concerns that a full repeal should be delayed until a replacement plan is fully-realized and a funding strategy is in place.
Orthofix announced both FDA and CE Mark approvals for its next-generation CervicalStim and SpinalStim bone growth stimulators (BGS), non-invasive devices that use low-level pulsed electromagnetic fields (PEMF) to enhance the healing process following orthopedic fusion surgeries.
New technology from the Georgia Institute of Technology targets vagus nerve stimulation (VNS) to improve its therapeutic benefit as a treatment for chronic inflammatory disease.
While remaining consistent with the 2015 draft guidance in many respects, the finalized guidance clarifies the scope of the policy following the passage of the 21st Century Cures Act and describes in greater detail how manufacturers may obtain classification of a new accessory type via the de novo process.
Researchers in Switzerland have produced real-life evidence that implanted devices could one day be powered by solar energy. Study participants who wore solar power measurement devices throughout their regular daily activities generated the energy required to power the average contemporary pacemaker, regardless of the weather, season, or age.
Nikon and Verily have signed a strategic partnership to co-develop advanced screening technology for eye diseases associated with diabetes. By pairing machine-learning capabilities with next-generation retinal imaging, the companies hope to offer earlier diagnosis of diabetic retinopathy and diabetic macular edema — two leading causes of blindness worldwide.
A team of Israeli scientists has further developed its breathalyzer technology, and a recent clinical study demonstrated an 86 percent success rate identifying 17 different diseases. The researchers’ nanoarray uses data collected from over 1,400 subjects to establish “breathprints” for diseases like cancer and multiple sclerosis, and then relies upon artificial intelligence (AI) technology to make a diagnosis.
U.S. anti-trust regulators are set to approve the $25 billion acquisition of St. Jude Medical by Abbott Laboratories, according Reuters sources. The deal was approved by European regulators in November, contingent on the companies’ divestment of two cardiovascular devices to Terumo.